Financial Ratios

SHARON BIO-MEDICINE LTD.

NSE : SHARONBIOBSE : 532908ISIN CODE : INE028B01029Industry : Pharmaceuticals & DrugsHouse : Private
BSE3.210 (0 %)
PREV CLOSE ( ) 3.21
OPEN PRICE ( ) 3.26
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 32550
TODAY'S LOW / HIGH ( )3.10 3.30
52 WK LOW / HIGH ( )3.1 4.65
NSE3.300 (0 %)
PREV CLOSE( ) 3.30
OPEN PRICE ( ) 3.30
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 8834
TODAY'S LOW / HIGH( ) 3.30 3.30
52 WK LOW / HIGH ( )2.95 4.5
Select year
ParticularsMar2023Mar2022Mar2016Jun2015Jun2014
Operational & Financial Ratios
   Earnings Per Share (Rs)33.0230.71-25.16-18.996.59
   CEPS(Rs)51.6950.22-23.89-17.388.05
   DPS(Rs)0.000.000.000.000.36
   Book NAV/Share(Rs)-1096.35-1130.02-17.177.9824.06
   Tax Rate(%)0.000.00-3.45-2.1117.86
Margin Ratios
   Core EBITDA Margin(%)13.0013.91-52.81-4.1211.95
   EBIT Margin(%)9.789.44-86.11-15.3010.91
   Pre Tax Margin(%)9.759.38-114.12-26.526.45
   PAT Margin (%)9.759.38-118.05-27.085.30
   Cash Profit Margin (%)15.2615.34-112.13-24.796.47
Performance Ratios
   ROA(%)6.213.46-34.50-20.796.53
   ROE(%)0.000.000.00-129.4631.44
   ROCE(%)10.224.32-27.65-12.8014.73
   Asset Turnover(x)0.640.370.290.771.23
   Sales/Fixed Asset(x)0.450.470.622.123.76
   Working Capital/Sales(x)-1.19-1.004.422.694.42
Efficiency Ratios
   Fixed Capital/Sales(x)2.242.141.610.470.27
   Receivable days49.57203.48358.72159.60106.88
   Inventory Days76.14215.36346.64136.5380.94
   Payable days184.44180.4550.1525.3819.85
Valuation Parameters
   PER(x)0.000.000.000.007.31
   PCE(x)0.000.00-0.46-0.725.99
   Price/Book(x)0.000.00-0.641.572.00
   Yield(%)0.000.000.75
   EV/Net Sales(x)3.794.123.771.150.93
   EV/Core EBITDA(x)24.7726.77-7.25-30.167.70
   EV/EBIT(x)38.7343.68-4.38-7.518.52
   EV/CE(x)3.764.391.320.951.05
   M Cap / Sales0.000.000.510.180.39
Growth Ratio
   Net Sales Growth(%)3.50-25.67-69.61-36.5224.00
   Core EBITDA Growth(%)2.74122.00-315.39-120.0030.78
   EBIT Growth(%)7.21108.15-71.11-188.9631.24
   PAT Growth(%)7.53105.91-32.47-424.4431.70
   EPS Growth(%)7.53222.07-32.47-387.98-86.83
Financial Stability Ratios
   Total Debt/Equity(x)-1.31-1.27-4.098.682.86
   Current Ratio(x)0.520.451.171.871.58
   Quick Ratio(x)0.400.330.641.020.95
   Interest Cover(x)307.04161.10-3.07-1.362.45
   Total Debt/Mcap(x)6.425.521.43

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.